| 晨会聚焦 | | --- | | 一、财信研究观点 | | 【市场策略】市场全天高开高走，大基建方向涨幅居前 | | 【基金研究】基金数据日跟踪 | | 【债券研究】债券市场综述 | | 二、重要财经资讯 | | 【宏观经济】6 月全社会用电量同比增长 5.4% | | 【宏观经济】央行开展 1707 亿元 7 天期逆回购操作 | | 【宏观经济】7 月 LPR 维持不变 | | 【财经要闻】截至 6 月我国互联网普及率达 79.7% | | 月全国网上零售额增长 【财经要闻】1-6 8.5% | | 【财经要闻】6 月全国销售彩票同比下降 2.6% | | 三、行业及公司动态 | | 【行业动态】6 月份用电量增长 5.4%，生活用电大幅增长 | | 【公司跟踪】百奥泰（688177.SH）：BAT4406F 注射液获得药物临床试验 | | 批准通知书 | | 【公司跟踪】新华医疗（600587.SH）：子公司一次性使用多通道单孔腹 | | 腔镜穿刺器获批 | | 【公司跟踪】天赐材料（002709.SZ）：与楚能新能源签订生产材料采购合 | | 作协议 | | 四、湖南经济动态 | | 【湘股动态】金 ...

Suspension - Jiangte Motor's actual controller is planning a change in company control, leading to stock suspension [1] - Sinochem Equipment is planning to issue shares to acquire 100% equity of multiple companies, resulting in stock suspension [1] Private Placement - Huafeng Technology plans to raise no more than 1 billion yuan through private placement for the expansion of high-speed line module projects [2] Equity Transfer - Longxin General's state-owned shareholder is transferring 15.52% of the company's shares from Yufu Capital without compensation [3] - Yunda Technology's controlling shareholder intends to transfer 10% of the company's equity to Zhixiang Dahang at a price of 9.01 yuan per share [4] External Investment and Daily Operations - Fuxin Technology's Micro TEC product has reached industry-leading performance and has passed product verification from a major telecommunications company, achieving bulk supply [5] - Dongfang Precision has signed a strategic cooperation agreement with Leju Robotics [6] - Hongxin Technology has signed a technology development and parts procurement contract with a leading domestic flying car company in the low-altitude economy [7] - Fuwei Co., Ltd. received a project notification from a well-known luxury brand manufacturer, with a project lifecycle expected to last 6-7 years and total sales amounting to 4.9 billion yuan [7] - Rainbowsoft Technology's actual controller proposed a cash dividend of no less than 60% of net profit for the 2025 interim period [8] - Samsung Medical's subsidiary won a transformer procurement framework contract in Brazil worth approximately 341 million yuan [9] - Chuling Information's subsidiary signed a framework contract for intelligent computing network integration [9] - Baotai's BAT4406F injection has received approval for clinical trials [9] - Junxin Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange [9] - Dongfang Precision has signed a strategic cooperation agreement with Leju Robotics [10] - Daikin Heavy Industry signed a 430 million yuan contract for offshore wind power monopile foundations in Europe [11] - Kunming Pharmaceutical Group's subsidiary obtained a drug registration certificate for carbonic acid sevelamer dry suspension [12] - Xiechuang Data has initiated preparations for overseas share issuance and application for listing on the Hong Kong Stock Exchange [13] - Health元's restructured anti-IL-17A/F humanized monoclonal antibody injection's phase III clinical trial has reached its primary research endpoint [14] - Beilu Zhikong plans to invest 600 million yuan to build an intelligent driving industrialization base for mining [15] - Jucan Optoelectronics reported a net profit of 117 million yuan for the first half of the year, a year-on-year increase of 3.43%, and plans a 10-for-4.5 stock split [16] Performance Changes - Jinghe Integration expects a net profit of 260 million to 390 million yuan for the first half of 2025, a year-on-year increase of 39.04% to 108.55% due to increased product sales and high capacity utilization [10] - Baismei anticipates a net profit of 33.11 million to 44.42 million yuan for the first half of 2025, a year-on-year increase of 100.07% to 168.38% driven by product structure optimization and international trade channel development [11] - Changying Tong expects a net profit of 26.12 million to 31.92 million yuan for the first half of 2025, a year-on-year increase of 72.12% to 110.33% due to significant growth in optical fiber device deliveries [12] - Mankun Technology expects a net profit of 60 million to 70 million yuan for the first half of 2025, a year-on-year increase of 53.98% to 79.64% as the company optimizes product and customer structure [13] - Canqin Technology anticipates a net profit of 51.3 million to 55.3 million yuan for the first half of 2025, a year-on-year increase of 50.14% to 61.85% due to new product development and market expansion [14] - Aerospace Huanyu expects a net profit of approximately 34.38 million yuan for the first half of 2025, a year-on-year increase of 50.59% driven by revenue growth and changes in product sales structure [15] - Keda Li expects a net profit of 750 million to 820 million yuan for the first half of 2025, a year-on-year increase of 15.73% to 26.53% due to increased sales of new energy vehicles [16] - Honghua Digital expects a net profit of 240 million to 260 million yuan for the first half of 2025, a year-on-year increase of 19.90% to 29.89% as traditional printing equipment transitions to digital printing [17] - Yangjie Technology anticipates a net profit of 552 million to 637 million yuan for the first half of 2025, a year-on-year increase of 30% to 50% due to growth in the semiconductor industry [18] - Haitai Ruisheng expects a net profit of 2.944 million to 4.416 million yuan for the first half of 2025, a year-on-year increase of 607.01% to 960.52% driven by rapid development in AI technology [19] - Zhongshi Technology expects a net profit of 116 million to 129 million yuan for the first half of 2025, a year-on-year increase of 85.01% to 105.75% due to recovery in consumer electronics market demand [20]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 本周 （7 月 14-7 月 20 日） ，国际顶尖学术期刊 Cell 共上线了 7 篇研究论文，其中 5 篇来自华人学 者，这些研究 发现了 腺相关病毒的一种替代受体 、 葡萄糖限制通过外泌体促进肿瘤肺转移 、 揭开大脑 如何实时指挥血液流动 、 pH 依赖性转录凝聚体对炎症反应的调节 、 揭开甲状腺激素的大脑转运之谜 。 腺相关病毒的一种替代受体 2025 年 7 月 14 日，北京大学生命科学学院 苏晓东 教授、悉尼大学 Charles G. Bailey 、 John E.J. Rasko 等作为共同通讯作者，在国际顶尖学术期刊 Cell 上发表了题为： An alternate receptor for adeno-associated viruses 的研究论文。 该研究发现了一种 腺相关病毒 （AAV） 的替代受体—— AAVR2 （CPD） ，其在 缺乏 AAVR 的情况下， 可恢复 E 分支 AAV （包括 AAV8） 的转导作 用，并为未分类的 AAV11 和 AAV12 提供了一条独立于 AAVR 的专属进入通道。此外，研究团队过表达了一个最小的功 ...

在腾盾科创的展台上，多名参展商正在询问模块化多用途无人机的产品信息，这些产品已广泛应用于应 急救援、气象服务、广域巡护、航空运输等领域。"这两天来展台了解产品、对接需求的企业挺多的， 包括国际国内关于物流运输、农林植保等领域的企业，也有想直接购买大型无人机的其他企业。"腾盾 科创分公司北京腾盾总经理许华伟表示。 链博会不仅赋能产业合作，还推动"智造"升级。兰剑智能的展台上，蜘蛛侠料箱机器人和T40拣选机器 人在4.5米高的立体货架之中快速穿行，协作完成货物的智能拣选，吸引与会者频频驻足。 腾盾科创在此次链博会创新融合展区参展，这一展区汇聚着十余家专精特新"小巨人"企业，集中展示无 人机全产业链。 "这次我们带来了公司自主研发的电源模块产品，可应用于无人机等多个行业。"皓文电子市场部相关负 责人介绍，公司希望通过链博会巩固品牌形象，寻求新的客户合作。 不远处，中恒景新展区展出的用高端碳纤维复合材料制造装备生产的无人机配套复合材料雷达支架也是 产业链上重要一环。公司总经理助理张猛猛表示，一些配套的上下游企业已经向公司表达合作意向。 ● 本报记者 熊彦莎 连润 王舒嫄 兰剑智能的智能货架系统吸引多位潜在客户；腾盾科 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 甲状腺激素 向大脑的充分输送对于正常的神经发育至关重要。 MCT8 和 OATP1C1 这两种溶质载体转运蛋白介导了甲状腺激素穿过血脑屏障 （BBB） 进入中枢 神经系统 （CNS） 。 MCT8 突变会导致 艾伦-赫恩登-达德利综合征 （AHDS） ，这是一种 X 连锁隐性遗传病，其特征为神经发育障碍和外周甲状腺功能亢进，而 OATP1C1 缺乏则 与大脑代谢降低和进行性神经退行性病变有关。 2025 年 7 月 17 日，贝勒医学院 黄鹏 翔 研究员 、美国 国立卫生研究院国家心肺血液研究所 江建森 研究员作为共同通讯作者，在国际顶尖学术期刊 Cell 上发 表了 题为： Structural insights into brain thyroid hormone transport via MCT8 and OATP1C1 的研究论文。 该研究通过对 MCT8 和 OATP1C1 的结构解析， 揭示了甲状腺素跨膜转运到大脑的机制。 在这项最新研究中，研究团队解析了 MCT8 和 OATP1C1 结合 活性甲状腺激素三碘甲腺原氨酸 （T3） 及其前体激素甲状腺素 （ ...

2025-07-16 10:25:32 作者：狼叫兽 对普通人如你我，"炒黄金"这三个字，咋听起来，神秘又遥远。事实呢？并不是！它其实没那么复杂！ 掌握正确的方法、选择合适的平台，并在实践中逐步积累经验，无任何基础的新人，也能从容上手。在 众多贵金属投资平台中，皇御贵金属凭借专业、稳健、服务贴心的特点，特别适合初学者入门，帮助新 手走好炒黄金的三步关键之路。 第二步：模拟交易，积累操作经验 对新手而言，知道如何操作远比单纯的理论更重要。皇御贵金属为所有注册用户提供免费模拟账户，这 是真正站在新手角度出发的服务。仅需几分钟时间，在皇御APP或官网，下载正版MT4，即可开始交 易。其模拟账户与真实账户在操作界面和市场数据上完全一致，投资者可在完全无风险的环境中进行真 实市场操作，练习下单、止盈止损设置、仓位控制等核心技能。 在模拟交易过程中，新手会逐步熟悉交易软件的界面布局、挂单方式、止盈止损等操作要点。皇御贵金 属的交易平台支持多设备登录，无论是电脑还是手机，都可实现流畅操作，确保用户可以在任何时间、 任何地点练习和操作。尤其官方APP，随时随地掌上查行情。超级便利性，对刚刚接触交易系统的新用 户来说尤为可贵， ...

Summary of Conference Call Notes Company Overview - The conference call focuses on Shanghai Baoxin Software Co., Ltd, a publicly listed software enterprise controlled by Baosteel Group, specializing in digital solutions for the steel and advanced materials industries [1] - The company has over 40 years of experience and aims to be a leader in industrial intelligence and smart manufacturing [1] Core Business Segments Information Technology Business - The IT business focuses on digital upgrades in manufacturing, providing comprehensive solutions for industries such as steel, non-ferrous metals, chemicals, and mining [3] - Utilizes the Baolian platform to integrate process control and digital intelligence, offering new-generation industrial software products [3] Automation Business - The automation segment emphasizes industrial automation, providing smart factory solutions through a fully domestic product system [4] - Integrates new technologies like industrial internet, AI, and edge computing to create a digital monitoring system for factories [4][5] Robotics Business - The robotics segment develops a complete product matrix for industrial robots, covering various applications in sectors like 3C, new energy, and metal processing [5] - Focuses on creating embedded applications for manufacturing processes and offers comprehensive solutions for the automotive industry [6] Smart Transportation Business - The smart transportation segment provides solutions for urban rail transit, integrating big data and AI for enhanced operational efficiency [6] - The company has received recognition for its innovative smart station technology, which has been implemented in multiple cities [7] Computing Power Center - The Baozhi Cloud brand represents the company's computing power center, offering comprehensive lifecycle management and infrastructure solutions [8] - Recently won a significant contract for an IDC project, reinforcing its market position in North China [8] Financial Performance - For 2024, the company reported total revenue of 13.644 billion yuan, with an average annual growth rate of approximately 16.12% from 2017 to 2024 [9] - The net profit for the year was 2.265 billion yuan, reflecting an 11% decrease compared to the previous year, attributed to macroeconomic conditions and industry impacts [9] - The weighted average return on equity for 2024 was 20.67%, showing slight decline from the previous year [9] Strategic Goals - The company aims to enhance its value through engineering excellence, product scalability, and platformization, focusing on high-quality development and becoming a leading industrial internet technology company [10]

点击下方 卡片 ，关注" 自动驾驶之心 "公众号 戳我-> 领取 自动驾驶近15个 方向 学习 路线 不少双非的同学都很迷茫。。。 实验室参与的工作有些落伍，现在无论是自动驾驶还是具身智能公司都需要实力比较强、背景比较好的同学。 以下是 知识星球 内部一位双非同学的提问，非常有代表性： 各位大佬们好，我目前是一个双非的研究生，我的研究方向是多传感器融合定位的，然后学过python，深 度学习，ros，但都学的不是很精，现在想多学一点为以后找工作用，感觉算法岗我的学历可能不太行，请 问各位大佬们我应该往哪个方向学比较好呢？学些什么知识呢？ 星主回答：你的技术栈都比较偏机器人一些，SLAM和ROS这块都可以尝试一下和机器人/具身智能打交道。这 块需求也比较大，可以做一些优化、集成类工作~ 另一方面，我们了解到大一些的公司各家的hc都不是很高，要求基本上都是端到端、大模型、VLA、强化学 习、3DGS这些比较前沿的方向。如果你做的是这块，是有机会的，很多tire 1的公司或者主机厂也正在follow前 沿的技术，大概是从无图往端到端转，差不多技术栈推迟1-2代。像LV融合、无图、BEV感知也确实都有在用， 但这块的 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [4]. Core Insights - In the first half of 2025, several CXO companies are expected to see year-on-year improvements in performance, suggesting potential investment opportunities [2][21]. - The pressure from the US interest rate hike cycle on new drug financing is gradually easing, leading to a recovery in overseas new drug development demand, which is beneficial for Chinese companies [2][21]. - The report highlights the resilience of gross margins for leading companies in the CXO sector, indicating a positive trend in external CDMO orders [2][21]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index rose by 1.82%, outperforming the CSI 300 index by 1.00 percentage points but underperforming the ChiNext index by 0.39 percentage points, ranking 16th among 31 sub-industries [1][13]. - The Hong Kong Hang Seng Healthcare Index increased by 0.05%, lagging behind the Hang Seng China Enterprises Index by 0.96 percentage points [1][13]. Company Performance Expectations - WuXi AppTec, a leading CXO company, expects to achieve approximately CNY 20.799 billion in revenue for the first half of 2025, a year-on-year increase of about 20.64%, with adjusted net profit expected to be around CNY 6.315 billion, up 44.43% year-on-year [19][21]. - Other companies like Boteng Co. and Aopumai also forecast revenue growth of 15%-20% and 23.25% respectively for the same period [19][20]. Investment Strategy - The report suggests a focus on three payment channels within the pharmaceutical industry: hospital payments, out-of-pocket payments, and overseas payments, with recommendations for companies like Heng Rui Pharmaceutical, Mindray Medical, and Yuyue Medical [2][21]. R&D Progress - Recent updates indicate that several companies are advancing in their clinical trials, with notable progress from companies like Baiyao and Huadong Medicine [25][26]. Financial Metrics - The pharmaceutical manufacturing industry reported a cumulative revenue of CNY 994.79 billion from January to May 2025, reflecting a year-on-year decline of 1.40% [52].

点击下方 卡片 ，关注" 自动驾驶之心 "公众号 戳我-> 领取 自动驾驶近15个 方向 学习 路线 1. 自我介绍 自我介绍环节主要是让双方进入快速面试状态，这块没什么特别注意的，别磕巴就好，主要聊聊个人基本信息、教育背景、工作经历和技 能特长等等。 2. 项目面 因为我简历上面写一个RAG项目，所以面试官主要围绕RAG进行提问： 最近面试了理想汽车大模型岗位，被面试官强度拉满了...不仅问到了很多大模型的基础，从通用大模型到大模型微调，再到自动驾驶多模 态大模型全方面被拷打，尤其是对大模型如何落地自动驾驶进行了很长时间的讨论。毕竟理想的VLM是国内首个上车的，这块的经验积累 还是比较丰富。 本文章主要记录了本小菜研找实习的坎坷历程，欢迎大佬们给建议！！！ 4. ... 通用大模型是面试的重点，面试官比较关心有没有横向对比近一年开源的SOTA大模型，这些模型在不同任务上有什么优劣势，以及大模型 微调比较细致的思考，这块涉及： 3. 技术问题回答 3.1 简单介绍一下大模型存在哪些问题？有什么好的解决方法？ 3.2 如何看待自动驾驶大模型？以及如何落地自动驾驶大模型？ 这块聊了很多自动驾驶大模型的工作，像经典 ...